麝香保心丸与通心络胶囊治疗冠状动脉粥样硬化性心脏病心绞痛的药物经济学评价  

A Pharmacoeconomic Evaluation of Shexiang Baoxin Pills and Tongxinluo Capsule in the Treatment of Coronary Atherosclerotic Cardiopathy Angina Pectoris

作　　者：王志军 吕冬梅 张桂娟 高志成 陈小菲 李勇 WANG Zhi-Jun;LV Dong-Mei;ZHANG Gui-Juan;GAO Zhi-Cheng;CHEN Xiao-Fei;LI Yong(Department of Cardiology,Affiliated Hospital of North China University of Science and Technology,Tangshan 063000,China)

机构地区：[1]华北理工大学附属医院心内科,河北唐山063000

出　　处：《中国药物经济学》2024年第8期30-37,43,共9页China Journal of Pharmaceutical Economics

摘　　要：目的评价麝香保心丸与通心络胶囊治疗冠状动脉粥样硬化性心脏病(CHD)心绞痛的成本-效果。方法检索国内外涉及麝香保心丸对比通心络胶囊治疗CHD心绞痛随机对照试验的相关已发表文献,经过筛选后进行质量评价,并采用Stata 16.0统计软件进行荟萃分析。此外,参考我国各省市区挂网药物价格并结合用药量来计算成本,进一步分析成本-效果比。结果最终纳入文献11篇,涉及受试者990例。与通心络胶囊相比,麝香保心丸症状有效率相差9%(95%CI:-5%~21%,P=0.23),心电图有效率相差12%(95%CI:1%~23%,P=0.03),表明麝香保心丸的症状有效率和心电图有效率优于通心络胶囊。基于全国平均情况进行增量成本-效果比分析,与通心络胶囊比较,麝香保心丸在改善临床症状方面的增量成本-效果比为-285.26,表明麝香保心丸更具经济性;敏感性分析结果显示,在全国大部分省市区与通心络胶囊相比,麝香保心丸在改善临床症状方面的增量成本-效果比均为负数,提示麝香保心丸具有显著的经济学优势。在全国范围内,麝香保心丸与通心络胶囊相比,在改善心电图结果方面的增量成本-效果比为-570.53,麝香保心丸表现出绝对的经济性优势;敏感性分析结果显示,在全国大部分省市区麝香保心丸与通心络胶囊相比,在改善心电图结果方面的增量成本-效果比均为负数,同样证明了麝香保心丸更具绝对经济性。结论在CHD心绞痛的临床治疗中,麝香保心丸在改善临床症状和心电图结果方面的效果均优于通心络胶囊,且在全国大部分省市区,麝香保心丸相比通心络胶囊具有绝对的经济性。Objective To evaluate the cost-effectiveness of Shexiang Baoxin Pill and Tongxinluo capsule in the treatment of coronary atherosclerotic heart disease(CHD)angina pectoris.Methods Randomized controlled trials involving Shexiang Baoxin Pill versus Tongxinluo capsule in the treatment of CHD angina pectoris at home and abroad were searched.Quality evaluation was conducted after screening,and meta-analysis was performed using Stata 16.0 statistical software.In addition,the cost is calculated by referring to the drug price of various provinces and autonomous regions in China and combining with the drug quantity,and the cost-effectiveness ratio is further analyzed.Results Finally,11 literatures were included,involving 990 subjects.Compared with Tongxinluo capsule,the symptom effective rate of Shexiangbaoxin Pill was 9%(95%CI:-5%~21%,P=0.23),and the electrocardiogram effective rate was 12%(95%CI:1%~23%,P=0.03),indicating that the symptom effective rate and electrocardiogram effective rate of Shexiangbaoxin Pill were better than that of Tongxinluo capsule.Based on the national average situation,the incremental cost-effectiveness ratio was analyzed.Compared with Tongxinluo capsule,the incremental cost-effectiveness ratio of Shexiang Baoxin Pill in improving clinical symptoms was-285.26,indicating that Shexiang Baoxin Pill was more economical.The results of sensitivity analysis showed that compared with Tongxinluo capsule in most provinces and autonomous regions of China,the incremental cost-effectiveness ratio of Shexiang Baoxin Pill in improving clinical symptoms was negative,suggesting that Shexiang Baoxin Pill has a significant economic advantage.Compared with Tongxinluo capsule,the incremental cost-effectiveness ratio of Shexiang Baoxin Pill in improving ECG results was-570.53,indicating that Shexiang Baoxin Pill showed absolute economic advantage.The results of sensitivity analysis showed that the incremental cost-effectiveness ratio of Shexiang Baoxin Pill to Tongxinluo capsule in improving ECG results was negative i

关 键 词：麝香保心丸 通心络胶囊 冠状动脉粥样硬化性心脏病 心绞痛 药物经济学 

分 类 号：R541.4[医药卫生—心血管疾病] R956[医药卫生—内科学]